Literature DB >> 29254286

Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL-1 family members.

I Robuffo1, E Toniato2, L Tettamanti3, F Mastrangelo4, G Ronconi5, I Frydas6, Al Caraffa7, S K Kritas8, P Conti9.   

Abstract

Innate immunity consists of physical and chemical barriers which provide the early defense against infections. Innate immunity orchestrates the defense of the host with cellular and biochemical proteins. Mast cells (MCs) are involved in innate and adaptive immunity and are the first line of defense which generates multiple inflammatory cytokines/chemokines in response to numerous antigens. MC-activated antigen receptor Fc-RI provokes a number of important biochemical pathways with secretion of numerous vasoactive, chemoattractant and inflammatory compounds which participate in allergic and inflammatory diseases. MCs can also be activated by Th1 cytokines and generate pre-formed and de novo inflammatory mediators, including TNF. IL-37 is an anti-inflammatory cytokine which binds IL-18R-alpha chain and reduces the production of inflammatory IL-1 family members. IL-37 down-regulates innate immunity by inhibiting macrophage response and its accumulation and reduces the cytokines that mediate inflammatory diseases. Here, we discuss the relationship between MCs, innate immunity, and pro-inflammatory and anti-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29254286

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  8 in total

1.  Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin.

Authors:  Alexandra Taracanova; Irene Tsilioni; Pio Conti; Errol R Norwitz; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-19       Impact factor: 11.205

Review 2.  Biology of interleukin-37 and its role in autoimmune diseases (Review).

Authors:  Huiqiong Zeng; Kaixia Zhou; Zhizhong Ye
Journal:  Exp Ther Med       Date:  2022-06-07       Impact factor: 2.751

Review 3.  Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers).

Authors:  Pio Conti; Alessandro Caraffa; Gianpaolo Ronconi; Chiara M Conti; Spiros K Kritas; Filiberto Mastrangelo; Lucia Tettamanti; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

Review 4.  Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37.

Authors:  P Conti; Al Caraffa; F Mastrangelo; L Tettamanti; G Ronconi; I Frydas; S K Kritas; T C Theoharides
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 8.755

5.  Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability.

Authors:  Donna W Lee; Shelly Zhong; Rama Pai; Julie Rae; Siddharth Sukumaran; Eric G Stefanich; Jeff Lutman; Estelle Doudement; Xiaoting Wang; Brandon Harder; Annemarie Lekkerkerker; Ann Herman; Wenjun Ouyang; Dimitry M Danilenko
Journal:  Pharmacol Res Perspect       Date:  2018-11-15

Review 6.  Interleukin-37: The Effect of Anti-Inflammatory Response in Human Coronary Artery Endothelial Cells.

Authors:  Xianfeng Yan; Bin Xie; Guihai Wu; Jing Hu; Di Wang; Xiangna Cai; Jilin Li
Journal:  Mediators Inflamm       Date:  2019-01-08       Impact factor: 4.711

7.  A new ratio derived from inflammasome markers can serve as a marker of assessment of glycemic index in children with Type 1 diabetes.

Authors:  Zhian M I Dezayee; Marwan S M Al-Nimer
Journal:  J Res Med Sci       Date:  2022-02-18       Impact factor: 1.852

Review 8.  An overview of mast cell pattern recognition receptors.

Authors:  Justyna Agier; Joanna Pastwińska; Ewa Brzezińska-Błaszczyk
Journal:  Inflamm Res       Date:  2018-06-16       Impact factor: 4.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.